StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy
As of the April 21 data cutoff, 67 of 124 evaluable patients treated with detalimogene (formerly EG-70) achieved a 54% complete response (CR) at any time, a rate that fell to 43% (52 of 121 evaluable patients) CR rate at six months. That compares with the 63% CR at any time and 62% CR rate at six months shown for the first 62 patients assessed, as announced by enGene in November 2025. The post StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy appea...
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.